Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt337PMID 23975665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study.

  2013cited by this paper
• The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease

  2012cited by this paper
• Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.

  2012cited by this paper
• Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

  2012cited by this paper
• Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).

  2012cited by this paper
• Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer

  2012cited by this paper
• Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.

  2012cited by this paper
• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  2012cited by this paper
• Thrombotic Microangiopathy with Targeted Cancer Agents

  2011cited by this paper
• Cholangiocarcinoma

  2010cited by this paper
• Genetics of biliary tract cancers and emerging targeted therapies.

  2010cited by this paper
• Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

  2010cited by this paper
• Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

  2010influential reference
• Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.

  2010cited by this paper
• Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

  2010cited by this paper
• Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

  2009cited by this paper
• Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

  2009cited by this paper
• Adjuvant therapy for completely resected stage II colon cancer.

  2008cited by this paper
• Mucinous Rectal Adenocarcinoma Can Be Associated to Tumor Downstaging after Preoperative Chemoradiotherapy

  2007cited by this paper
• Effects of radiotherapy on different histopathological types of rectal carcinoma

  2006cited by this paper
• Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma

  2006cited by this paper
• Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.

  2005cited by this paper
• Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

  2004cited by this paper
• Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

  2004cited by this paper
• Cholangiocarcinoma: Current concepts and insights

  2003cited by this paper
• Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

  2002cited by this paper
• Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma

  2001cited by this paper
• Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver

  2000cited by this paper
• Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

  2000cited by this paper
• Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

  1996cited by this paper

• Molecular Alterations and Pathways in Intrahepatic Cholangiocarcinoma: Available Evidence and New Perspectives

  2025cites this paper
• Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma.

  2025cites this paper
• Targeted therapies and immunotherapies for unresectable cholangiocarcinoma

  2025cites this paper
• Identification of internalizing ScFvs for EGFR inhibition and apoptosis induction in cholangiocarcinoma cells

  2025cites this paper
• Cholangiocarcinoma, sequential chemotherapy, and prognostic tests

  2024cites this paper
• Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma

  2023cites this paper
• Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis

  2023cites this paper
• Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision

  2022cites this paper
• Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma.

  2022cites this paper
• Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis

  2022influential citation
• Combination Therapies for Advanced Biliary Tract Cancer

  2022cites this paper
• Will Advanced Cholangiocarcinoma Become a Targetable Malignancy?

  2021cites this paper
• Bioinformatics Combined with Quantitative Proteomics Analyses and Identi�cation of Potential Biomarkers in Cholangiocarcinoma

  2021cites this paper
• Current and emerging therapies for advanced biliary tract cancers.

  2021cites this paper
• Primary Sclerosing Cholangitis–Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity

  2021cites this paper
• Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis

  2021cites this paper
• OTT_A_317514 3895..3901

  2021cites this paper
• Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation

  2021cites this paper
• Intrahepatic Cholangiocarcinoma: Evolving Concepts and Medical Treatment

  2021cites this paper
• Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.

  2021cites this paper
• Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

  2020cites this paper
• Therapy for advanced cholangiocarcinoma: Current knowledge and future potential

  2020cites this paper
• Systemic treatment options for advanced biliary tract carcinoma

  2020cites this paper
• Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience

  2020cites this paper
• The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.

  2020cites this paper
• Clinical Trials and Novel/Emerging Treatment

  2019cites this paper
• Biliary tract cancer prognostic and predictive genomics.

  2019cites this paper
• Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis

  2019cites this paper
• Systemic Therapy

  2019cites this paper
• Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report

  2018cites this paper
• New developments in systemic therapy for advanced biliary tract cancer

  2018cites this paper
• Surgical Management of Hilar Cholangiocarcinoma

  2018cites this paper
• Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis

  2018cites this paper
• Intrahepatic Cholangiocarcinoma

  2018cites this paper
• Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

  2018cites this paper
• A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan

  2017cites this paper
• New Horizons for Precision Medicine in Biliary Tract Cancers.

  2017cites this paper
• Emerging therapies for the treatment of cholangiocarcinoma

  2017cites this paper
• Radiomics and imaging genomics in precision medicine

  2017influential citation
• Aktuelle Therapieoptionen beim Cholangiokarzinom

  2017cites this paper
• New molecular and immunotherapeutic approaches in biliary cancer

  2017cites this paper
• Signaling pathways as therapeutic targets in biliary tract cancer

  2017cites this paper
• Cholangiocarcinoma.

  2017cites this paper
• Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma

  2016cites this paper
• Novel investigational therapies for treating biliary tract carcinoma

  2016cites this paper
• [Medical management of cholangiocarcinomas in 2015].

  2016cites this paper
• Targeted Therapeutics against Biliary Cancer Elicit Concurrent Tumor Extrinsic Effects on Immune Suppression and Cancer Cachexia

  2016cites this paper
• Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

  2016cites this paper
• Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in KRAS wild-type Advanced Biliary Tract Cancer: a randomized, Phase II trial (Vecti-BIL Study)

  2016cites this paper
• Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells.

  2016cites this paper
• Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation

  2016cites this paper
• Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores.

  2016cites this paper
• Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma

  2016cites this paper
• The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets

  2016cites this paper
• Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design

  2016cites this paper
• A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

  2015cites this paper
• Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies

  2015cites this paper
• Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer

  2014cites this paper
• Immunotherapy for Gastrointestinal Malignancies

  2014cites this paper
• Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.

  2013cites this paper